President and Chief Executive Officer · Karuna Therapeutics, Inc. (KRNA)

Steven Paul

A named executive officer of Karuna Therapeutics in every fiscal year CompBrief holds from FY2020 to FY2022. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2022

$11,224,103

Salary $700,000Stock awards $0

FY2021: $13,136,960

1st of 5 named executive officers at Karuna Therapeutics by FY2022 total.

5 named officers on file for Karuna Therapeutics, FY2022

Steven Paul’s pay file — $29

  • 3 fiscal years of pay, line by line
  • 1 equity grant, each cited to its filing
  • KRNA’s disclosed peer group of 18 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Karuna Therapeutics’s whole pay program stands against its peers

  • Karuna Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on KRNA→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 27, 2023 (DEF 14A). Insider transactions since that proxy, current to 2026-11-21.

Free

Get Steven Paul’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Steven Paul compensation by year

Karuna Therapeutics Summary Compensation Table · all 3 fiscal years held
In US dollars, as Karuna Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2020FY2021FY2022
Salary$575,000$645,000$700,000
Bonus$0$0$0
Stock awards$0$0$0
Option awards$8,031,191$11,933,397$9,905,953
Non-equity incentive$287,500$549,863$609,000
Pension and deferred compensation$0$0$0
All other$8,550$8,700$9,150
Total$8,902,241$13,136,960$11,224,103

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Karuna Therapeutics, Inc. DEF 14A filed April 27, 2023, accession 0000950170-23-014979, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Karuna Therapeutics, Inc. filed document, accession 0000950170-23-014979. Every figure is read from that document and cited to the page and table it appears in. Filed April 27, 2023.

$8.9M
$13.1M
$11.2M
FY20
FY21
FY22
SalaryNon-equity incentiveOption awardsAll other

Equity holdings

unvested awards at FY2022 year-end
TypeUnvested unitsValue at year-endExercise price
Option43,750—$99.72
Option91,040—$131.64
Option146,900—$111.97

Per the Outstanding Equity Awards at Fiscal Year-End table in Karuna Therapeutics, Inc.'s FY2022 proxy; value at the fiscal year-end close, as the company printed it.

Insider transactions since the last proxy

30 Form 4 lines since the FY2022 proxy (filed April 27, 2023)
current to 2026-11-21 · updated nightly
DateTransactionPlanSharesPriceHeld after
2024-03-18Disposition to the issuer derivative—136,094$322.960
2024-03-18Disposition to the issuer derivative—757,045$322.730
2024-03-18Disposition to the issuer—30,304$330.000
2024-03-18Disposition to the issuer—33,882$330.000
2024-03-18Disposition to the issuer—30,304$330.000
2024-03-18Disposition to the issuer—35,877$330.000
2024-03-18Disposition to the issuer—2,046$330.008,550
2024-03-18Disposition to the issuer derivative—616,703$314.000

The 8 most recent of 30 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →

Karuna Therapeutics’s named executive officers, FY2022

as the company reported each
Named executive officerRoleFY2022 total
Steven Paul · this pagePresident and Chief Executive Officer$11,224,103
Andrew MillerChief Operating Officer$5,774,890
Stephen BrannanChief Medical Officer$4,413,379
Troy IgnelziChief Financial Officer$4,006,465
Charmaine LykinsChief Commercial Officer$759,650

Board service

Karuna Therapeutics board · FY2022

How this board is paid

Company policy: Karuna Therapeutics pays directors a $45,000 cash retainer. As stated in Karuna Therapeutics's FY2022 proxy.

The full Karuna Therapeutics compensation record

free company brief

This page is one person within Karuna Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the Karuna Therapeutics proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Karuna Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Steven Paul's compensation dossier · One-time report. No refunds.